12:00 AM
 | 
Jan 28, 2013
 |  BioCentury  |  Emerging Company Profile

Moderna: Funding the messenger

Moderna developing mRNA technology for faster, cheaper therapeutic proteins

Moderna Therapeutics Inc. expects its messenger RNA Therapeutics platform can reduce the time and expense of producing therapeutic proteins compared with recombinant technologies.

The company delivers modified mRNAs by subcutaneous or intramuscular injection, and the molecules are translated into therapeutic proteinsin vivo.

Moderna's chemical modifications allow the mRNAs to elude the body's innate immune response. The modified mRNAs also are encapsulated in liposomes or cationic lipids to avoid degradation in the body.

According to President and CEO Stephane Bancel, the platform is "technologically and financially superior" to recombinant protein technologies.

Standard technologies are limited to proteins that work in the extracellular...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >